News Archives - Insights

Diagnostic ecosystem boosts access to timely Alzheimer’s disease testing

Barbara J. Toman — Mon, 21 Oct 2024 13:15:00 +0000

Mayo Clinic Laboratories has developed a cutting-edge suite of Alzheimer's disease testing. The newest assays use blood samples, avoiding the need for lumbar punctures to obtain cerebrospinal fluid. The testing suite exemplifies Mayo Clinic Laboratories' innovative business approach. As a platform company, Mayo Clinic is creating a diagnostics ecosystem to meet a wide range of testing needs and help physicians order the right tests for their patients.

The post Diagnostic ecosystem boosts access to timely Alzheimer’s disease testing appeared first on Insights.

Plasma Test Increases Access to Alzheimer’s Testing: Alicia Algeciras-Schimnich, Ph.D.

Luci Gens — Thu, 10 Oct 2024 13:00:00 +0000

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Alicia Algeciras-Schimnich, Ph.D., a professor of laboratory medicine and pathology at Mayo Clinic and co-director of the Clinical Immunoassay Laboratory. They discuss Mayo Clinic’s plasma test for detecting Alzheimer’s disease and how […]

The post Plasma Test Increases Access to Alzheimer’s Testing: Alicia Algeciras-Schimnich, Ph.D. appeared first on Insights.

Meet Mayo Clinic Experts at the 65th ASH Annual Meeting & Exposition

Carly Mouzes — Tue, 07 Nov 2023 18:38:27 +0000

Mayo Clinic Laboratories is excited to participate in the 65th ASH Annual Meeting & Exposition, which will take place in San Diego on Dec. 9–12, 2023.

The post Meet Mayo Clinic Experts at the 65th ASH Annual Meeting & Exposition appeared first on Insights.

Unique collaboration advances discoveries for rare disease

Luci Gens — Tue, 24 Oct 2023 21:00:00 +0000

The nonprofit patient advocacy group called The MOG Project supports patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), which is a rare and debilitating central nervous system demyelinating disorder. A team of Mayo Clinic neurologists, neuro-ophthalmologists, and the Autoimmune Neurology Laboratory at Mayo Clinic share a unique relationship with The MOG Project as they harness the power of patients’ experiences with MOGAD and their biospecimen data to advance the science behind this disease.

The post Unique collaboration advances discoveries for rare disease appeared first on Insights.

Database of unsolved patient sequencing results yields new answers

Luci Gens — Tue, 10 Oct 2023 18:38:27 +0000

Mayo Clinic launched an automated system called RENEW — reanalysis of negative whole-exome/genome data — in 2022 that tracks newly published discoveries of disease-causing genetic variants. Every three months, the system automatically uploads these new scientific findings from around the world, which are then compared to the Mayo Clinic Center for Individualized Medicine’s database of unsolved patient sequencing results. This comparison helps to identify potentially significant developments that could lead to a new diagnosis for a patient with a rare genetic disorder.

The post Database of unsolved patient sequencing results yields new answers appeared first on Insights.

Ceramide testing provides algorithmic score for heart attack risk

Luci Gens — Tue, 26 Sep 2023 18:40:07 +0000

Mayo Clinic Laboratories offers a ceremide test to advise patients and their clinicians of the potential risk of heart attack. Using liquid chromatography-mass spectrometry technology, the test renders an algorithmic score after sorting through molecular compounds of ceramides of cardiovascular interest. Ceramide testing can be used alongside traditional blood tests to investigate risk factors of coronary artery disease.

The post Ceramide testing provides algorithmic score for heart attack risk appeared first on Insights.

Melanoma panel expands ability to diagnose tumors

Kevin Ritchart — Tue, 15 Aug 2023 18:41:54 +0000

Mayo Clinic Laboratories’ MayoComplete Melanoma Panel is a comprehensive test that better informs the prognosis and treatment of melanoma. It can be applied to unusual tumors that haven’t yet been identified as melanoma as well as melanomas with complex molecular structures.

The post Melanoma panel expands ability to diagnose tumors appeared first on Insights.

Specialized BioPharma accessioning team collaborates for quality assurance

Nicole Holman — Tue, 08 Aug 2023 18:45:21 +0000

At Mayo Clinic, quality is not an act, it’s a habit. This commitment extends into BioPharma Diagnostics, where a team of four quality assurance assistants and three lab processing assistants has recently come together as the BioPharma Accessioning Pod. Their focus includes accommodating the unique requirements of BioPharma clinical trials and research samples during accessioning and sharing data and findings with the BioPharma Diagnostics team.

The post Specialized BioPharma accessioning team collaborates for quality assurance appeared first on Insights.

Expanded colorectal cancer panel tests more genes

Kevin Ritchart — Tue, 01 Aug 2023 18:50:14 +0000

Mayo Clinic Laboratories has developed a new colorectal cancer test, the MayoComplete Colorectal Cancer Panel (Mayo ID: MCCRC), in response to the latest recommendations for testing and treatment from the American Society of Clinical Oncology.

The post Expanded colorectal cancer panel tests more genes appeared first on Insights.

GIST panel detects more gene mutations

Kevin Ritchart — Tue, 18 Jul 2023 18:52:15 +0000

The MayoComplete Gastrointestinal Stromal Tumor (GIST) Panel, Next-Generation Sequencing, Tumor evaluates for somatic mutations in solid tumor samples and determines microsatellite instability to confirm a diagnosis of GIST.

The post GIST panel detects more gene mutations appeared first on Insights.